Predictors of survival for breast cancer patients with a BRCA1 mutation-Reference-Cited by-同舟云学术

Predictors of survival for breast cancer patients with a BRCA1 mutation

Published:2017-12-15 Issue:2 Volume:168 Page:513-521
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Narod Steven A.,Huzarski Tomasz,Gronwald Jacek,Byrski Tomasz,Marczyk Elzbieta,Cybulski Cezary,Szwiec Marek,Wisniowski Rafal,Birkenfeld Bozena,Kilar Ewa,Sibilski Robert,Sun Ping,Lubinski Jan

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-017-4605-x/fulltext.html

Reference16 articles.

1. Jonasson JG, Stefansson OA, Johannsson OT, Sigurdsson H, Agnarsson BA, Olafsdottir GH, Alexiusdottir KK, Stefansdottir H, Munoz Mitev R, Olafsdottir K, Olafsdottir K, Arason A, Stefansdottir V, Olafsdottir EJ, Barkardottir RB, Eyfjord JE, Narod SA, Tryggvadóttir L (2016) Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. Br J Cancer 115(7):776–783

2. Cybulski C, Kluźniak W, Huzarski T, Wokołorczyk D, Kashyap A, Jakubowska A, Szwiec M, Byrski T, Dębniak T, Górski B, Sopik V, Akbari MR, Sun P, Gronwald J, Narod SA (2015) Lubiński J; Polish Hereditary Breast Cancer Consortium. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol 16(6):638–644

3. Marcus JN, Watson P, Page DL, Narod SA, Tonin P, Lenoir GM, Serova O, Lynch HT (1997) BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat 44:275–277

4. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storger-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Bignon YJ, Struewing JP, Spurr NK, Bishop DT, Klijn JG, Devilee P et al (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138–1145

5. Narod SA, Metcalfe K, Lynch HT, Ghadirian P, Robidoux A, Tung N, Gaughan E, Kim-Sing C, Olopade OI, Foulkes WD, Robson M, Offit K, Jakubowska A, Byrski T, Huzarski T, Sun P, Lubinski J (2013) Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat 138(1):273–279

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Choices for cancer prevention for women with a BRCA1 mutation? a personal view;Hereditary Cancer in Clinical Practice;2023-11-29

2. The APOBEC3B c.783delG Truncating Mutation Is Not Associated with an Increased Risk of Breast Cancer in the Polish Population;Genes;2023-06-24

3. PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants;npj Breast Cancer;2023-05-12

4. Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers;Nature Communications;2023-04-07

5. The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations;British Journal of Cancer;2022-03-07